Results 51 to 60 of about 528,594 (306)

Prospects for non-immunological molecular therapeutics in melanoma [PDF]

open access: yes, 2010
In 2006 there were 60,000 new cases of cutaneous melanoma in the European Union and 13,000 deaths (www.europeancancerleagues.org). Currently available systemic treatment options for metastatic melanoma, including both cytotoxic and immunologic therapies,
Tryfonopoulos, Dimitrios   +5 more
core  

Melanoma-associated adhesion molecule MUC18/MCAM (CD146) and transcriptional regulator Mader in normal human CNS [PDF]

open access: yes, 1998
The proteins MUC18 and Mader have been identified as markers of tumor progression in melanoma cells, MUC18, also known as MCAM (melanoma cell adhesion molecule) and as CD146 (endothelial antigen), is a cell adhesion molecule belonging to the ...
Müller, Norbert   +7 more
core   +1 more source

22 | Surgical radicality and reconstructive techniques in melanoma and non-melanoma skin cancer

open access: yesDermatology Reports
Background: This prospective case series evaluated the clinical outcomes of skin micro-fragment therapy in managing the excision of local advanced skin cancer. Recently, skin micro-fragment therapy has emerged as a promising alternative of classical skin
Italian Melanoma Intergroup
doaj   +1 more source

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

open access: yesMolecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola   +11 more
wiley   +1 more source

Identification of new genes associated with melanoma

open access: yes, 2011
Purpose: Repeated failures in melanoma therapy made clear that the molecular mechanisms leading to melanoma are still poorly understood. Here, we aim to provide a more comprehensive understanding of the transcriptional profiles and signaling pathways ...
Mauerer, Andreas
core   +1 more source

18 | Surgical management of pregnancy-associated melanoma: a single institution experience with thirty-three pregnant patients

open access: yesDermatology Reports
Background: Pregnancy-associated melanoma (PAM) has been associated with poorer outcomes, although the prognostic role of pregnancy remains controversial. Management of PAM is challenging, as no established guidelines are available.
Italian Melanoma Intergroup
doaj   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

open access: yesMolecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim   +3 more
wiley   +1 more source

Vitamins and Melanoma [PDF]

open access: yesCancers, 2015
A tremendous amount of information was published over the past decades in relation to the role of vitamins in various neoplastic diseases. In particular, several studies showed an inverse relationship between selected vitamins intake and cancer risk.
Russo, Irene   +2 more
openaire   +2 more sources

The Asp84GIu variant of the melanocortin 1 receptor (MC1R)is associated with melanoma

open access: yes, 1996
Melanocyte stimulating hormone (MSH) plays an important role in determining the cutaneous response to ultraviolet radiation and may also influence melanoma progression.
Thody, Anthony J.   +10 more
core   +1 more source

‘I am not someone who gets skin cancer’: Risk, time and malignant melanoma [PDF]

open access: yes, 2013
‘Delay’ is a term used in the cancer literature since the 1930s to describe the period between self-detection of a concerning sign of possible disease and presentation to a health professional.
Heyman, Bob   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy